Responsewhen BCR-ABL1 (IS)is <0.01%Non-pharmacologicaltreatment forCMLPatients havepresence of thisBCR-ABLproteinindicative ofCML Translocationbetweenthese twochromosomesoccur in CMLNumber ofblastspresent inacceleratedphaseThe numberof distinctclinicalphases inCMLDrug classthatrevolutionizedCMLtreatmentI failed 3lines of TKIs,I can try thisagent nextI avoid thisdrug classwith bosutinib,nilotinib anddasatinibThelandmarkfor thefirst TKIPercentageof blastspresent inthe blastphaseI want toavoid thisTKI if I donot wantdiarrheaTKIs aremajorsubstratesfor this liverenzymeI have theT315I mutationbut also haveelevated lipaseWhen togive H2RAswithdasatinibTherecommendedcriteria usedfor acceleratedphase60-70% ofpatients withCML presentwith thissymptomThe scoringsystem usedin chronicphaseTreatmentfor blastphaseCMLAfter 3months, I have3% BCR-ABL,I have this TKIresponseThe current5-yearoverallsurvival rateof CMLThis TKI hasthe mostmetabolicsyndromeToo many ofthese bloodcells areabnormal inCMLModerateto highemetogenicrisk TKIsResponsewhen BCR-ABL1 (IS)is <0.01%Non-pharmacologicaltreatment forCMLPatients havepresence of thisBCR-ABLproteinindicative ofCML Translocationbetweenthese twochromosomesoccur in CMLNumber ofblastspresent inacceleratedphaseThe numberof distinctclinicalphases inCMLDrug classthatrevolutionizedCMLtreatmentI failed 3lines of TKIs,I can try thisagent nextI avoid thisdrug classwith bosutinib,nilotinib anddasatinibThelandmarkfor thefirst TKIPercentageof blastspresent inthe blastphaseI want toavoid thisTKI if I donot wantdiarrheaTKIs aremajorsubstratesfor this liverenzymeI have theT315I mutationbut also haveelevated lipaseWhen togive H2RAswithdasatinibTherecommendedcriteria usedfor acceleratedphase60-70% ofpatients withCML presentwith thissymptomThe scoringsystem usedin chronicphaseTreatmentfor blastphaseCMLAfter 3months, I have3% BCR-ABL,I have this TKIresponseThe current5-yearoverallsurvival rateof CMLThis TKI hasthe mostmetabolicsyndromeToo many ofthese bloodcells areabnormal inCMLModerateto highemetogenicrisk TKIs

Chronic Myeloid Leukemia BINGO - Call List

(Print) Use this randomly generated list as your call list when playing the game. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
B
2
O
3
B
4
G
5
O
6
O
7
N
8
O
9
I
10
G
11
B
12
B
13
I
14
N
15
G
16
N
17
G
18
B
19
I
20
I
21
I
22
O
23
N
24
G
  1. B-Response when BCR-ABL1 (IS) is <0.01%
  2. O-Non-pharmacological treatment for CML
  3. B-Patients have presence of this BCR-ABL protein indicative of CML
  4. G-Translocation between these two chromosomes occur in CML
  5. O-Number of blasts present in accelerated phase
  6. O-The number of distinct clinical phases in CML
  7. N-Drug class that revolutionized CML treatment
  8. O-I failed 3 lines of TKIs, I can try this agent next
  9. I-I avoid this drug class with bosutinib, nilotinib and dasatinib
  10. G-The landmark for the first TKI
  11. B-Percentage of blasts present in the blast phase
  12. B-I want to avoid this TKI if I do not want diarrhea
  13. I-TKIs are major substrates for this liver enzyme
  14. N-I have the T315I mutation but also have elevated lipase
  15. G-When to give H2RAs with dasatinib
  16. N-The recommended criteria used for accelerated phase
  17. G-60-70% of patients with CML present with this symptom
  18. B-The scoring system used in chronic phase
  19. I-Treatment for blast phase CML
  20. I-After 3 months, I have 3% BCR-ABL, I have this TKI response
  21. I-The current 5-year overall survival rate of CML
  22. O-This TKI has the most metabolic syndrome
  23. N-Too many of these blood cells are abnormal in CML
  24. G-Moderate to high emetogenic risk TKIs